Table 2.
Odds ratios from multilevel logistic regression analyses of reporting side effects after COVID-19 vaccination adjusted for age, sex, first or second injection, and type of vaccine (n = 266) (COVID-PCD study, May 2021).
| OR | Lower 95% CI | Upper 95% CI | p-Value | |
|---|---|---|---|---|
| No side effects | ||||
| Age (continuous, per year increase) | 0.98 | 0.95 | 1.00 | 0.126 |
| Sex (female vs. male) | 1.80 | 0.72 | 4.50 | 0.208 |
| Injection (second vs. first) | 1.57 | 0.79 | 3.11 | 0.198 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 2.34 | 0.61 | 8.97 | 0.215 |
| AstraZeneca | 0.89 | 0.33 | 2.42 | 0.818 |
| Local pain/swelling | ||||
| Age (continuous, per year increase) | 0.99 | 0.96 | 1.01 | 0.320 |
| Sex (female vs. male) | 1.58 | 0.72 | 3.49 | 0.249 |
| Injection (second vs. first) | 1.45 | 0.86 | 2.45 | 0.168 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 3.32 | 1.11 | 9.92 | 0.032 |
| AstraZeneca | 0.54 | 0.22 | 1.30 | 0.167 |
| Tiredness | ||||
| Age (continuous, per year increase) | 0.99 | 0.97 | 1.01 | 0.374 |
| Sex (female vs. male) | 1.54 | 0.81 | 2.93 | 0.190 |
| Injection (second vs. first) | 2.19 | 1.33 | 3.61 | 0.002 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 2.95 | 1.23 | 7.09 | 0.016 |
| AstraZeneca | 1.12 | 0.55 | 2.29 | 0.751 |
| Fever | ||||
| Age (continuous, per year increase) | 0.97 | 0.95 | 0.99 | 0.015 |
| Sex (female vs. male) | 0.90 | 0.43 | 1.90 | 0.791 |
| Injection (second vs. first) | 3.12 | 1.64 | 5.94 | 0.001 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 5.64 | 2.06 | 15.42 | 0.001 |
| AstraZeneca | 7.57 | 2.93 | 19.53 | <0.001 |
| Headache | ||||
| Age (continuous, per year increase) | 0.98 | 0.96 | 1.00 | 0.052 |
| Sex (female vs. male) | 1.73 | 0.83 | 3.62 | 0.147 |
| Injection (second vs. first) | 2.31 | 1.33 | 4.00 | 0.003 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 3.15 | 1.21 | 8.20 | 0.019 |
| AstraZeneca | 6.30 | 2.65 | 15.00 | <0.001 |
| Muscle/bone pain (not around injection site) | ||||
| Age (continuous, year increase) | 0.97 | 0.95 | 0.99 | 0.003 |
| Sex (female vs. male) | 0.79 | 0.45 | 1.38 | 0.403 |
| Injection (second vs. first) | 1.59 | 0.99 | 2.56 | 0.057 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 2.34 | 1.11 | 4.96 | 0.026 |
| AstraZeneca | 4.73 | 2.34 | 9.53 | <0.001 |
| Other | ||||
| Age (continuous, per year increase) | 1.01 | 0.97 | 1.04 | 0.751 |
| Sex (female vs. male) | 1.34 | 0.45 | 4.01 | 0.604 |
| Injection (second vs. first) | 0.68 | 0.78 | 3.61 | 0.183 |
| Vaccine (ref: Pfizer-BioNTech) | ||||
| Moderna | 3.93 | 0.95 | 16.19 | 0.058 |
| AstraZeneca | 4.22 | 1.24 | 14.38 | 0.021 |